Novo Nordisk A/S (LON:0TDD)

Market Cap	128.28B -46.2%
Revenue (ttm)	36.10B +6.4%
Net Income	11.97B +1.4%
EPS	2.69 +1.8%
Shares Out	n/a
PE Ratio	10.72
Forward PE	11.89
Dividend	0.97 (2.47%)
Ex-Dividend Date	Mar 30, 2026

Volume	85,318
Average Volume	196,634
Open	39.16
Previous Close	39.04
Day's Range	38.02 - 39.46
52-Week Range	35.09 - 82.09
Beta	0.27
RSI	49.90
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 69,505
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0TDD

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK